CXCR1 and colorectal carcinoma: PDGF-CC could be a useful biomarker to choose the type of adjuvant chemotherapy in CRC patients after curative surgery; intensive adjuvant chemotherapy could be relevant to CRC patients with high levels of PDGF-CC even if they do not have other common risk factors for recurrence.